Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.46 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6922628 | 0.86 | CYP1A2 (0.55) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL8395124 | 0.84 | GSTP1 (0.50) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL9831511 | 0.83 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL8394925 | 0.83 | ERN1 (0.44) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL23092512 | 0.80 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL30876805 | 0.80 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL8781039 | 0.80 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL6191726 | 0.80 | PDE7A (0.62) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL29900461 | 0.80 | MEN1 (0.60) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL29900473 | 0.80 | PDE7A (0.62) | ALDH1A1MEN1KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425015-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6825208-B2 | SELECTIVE INHIBITORS OF SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR VIIA; MODULATION OF THE COAGULATION CASCADE. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1425015-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6703387-B2 | STYRYLBENZODIAZEPINES | HOFFMANN-LA ROCHE INC. | 2004-03-09 | — | — | US | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
| EP-1299364-A1 | BENZODIAZEPINES AS INHIBITORS OF HPV E1 HELICASE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-09 | — | — | EP | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| US-6518268-B1 | Telomerase inhibitors and methods of their use | GERON CORPORATION | 2003-02-11 | — | — | US | disclosed |
| US-20020128262-A1 | Inhibitors of HPV E1 helicase enzyme | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2002-09-12 | — | — | US | disclosed |
| WO-2002000632-A1 | BENZODIAZEPINES AS INHIBITORS OF HPV E1 HELICASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-03 | — | — | WO | disclosed |
| CN-1321153-A | telomerase inhibitors and methods of use thereof | GERON CORP (US) | 2001-11-07 | — | — | CN | disclosed |
| WO-2001002377-A9 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORP (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-1109796-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | Geron Corporation (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001002377-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
| US-5994563-A | THIOPHENE DERIVATIVES, IMMUNOSUPPRESSANTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | TFPI, TFPI2, SERPINC1 | ALDH1A1 2602/4885MEN1 2267/4885KMT2A 1472/4885 |
| US-20020128262-A1 | Inhibitors of HPV E1 helicase enzyme | DHX15, DHX35, DHX36 | ALDH1A1 589/4885MEN1 1769/4885KMT2A 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.